맞춤형 의료 시장 : 시장 규모, 점유율, 성장, 산업 분석, 지역 인사이트, 예측(2026-2034년)

Growth Factors of personalized medicine Market

The global personalized medicine market was valued at USD 214.44 billion in 2025 and is projected to grow from USD 233.87 billion in 2026 to USD 587.02 billion by 2034, registering a CAGR of 12.19% during the forecast period. The market is expanding rapidly due to the increasing adoption of genomic testing, companion diagnostics, biomarker-based therapies, and AI-driven clinical decision support systems. Personalized medicine enables healthcare providers to tailor treatments according to a patient's genetic, molecular, and clinical profile, improving treatment effectiveness and reducing adverse outcomes.

North America dominated the market in 2025 with a 39.11% market share, supported by strong genomics infrastructure, widespread use of targeted therapies, and advanced healthcare systems.

Market Trends

One of the most significant trends in the personalized medicine industry is the growing adoption of targeted therapies. Healthcare providers are increasingly shifting away from traditional one-size-fits-all treatment approaches toward biomarker-guided therapies. The expansion of companion diagnostics and molecular profiling technologies is helping physicians identify suitable patients for specific treatments, particularly in oncology. This trend is encouraging pharmaceutical companies to invest heavily in precision drug development and targeted treatment solutions.

Market Drivers

Increasing Prevalence of Chronic and Genetic Diseases

The rising burden of chronic diseases such as cancer, cardiovascular disorders, diabetes, and respiratory diseases is driving demand for personalized healthcare solutions. In addition, improved genomic sequencing technologies are enabling earlier diagnosis of rare and genetic disorders. According to NIH data published in 2025, rare diseases affect approximately 25-30 million Americans, highlighting the growing need for personalized diagnostic and treatment approaches.

Market Restraints

High Treatment Costs

Despite strong growth potential, the market faces challenges related to the high cost of personalized therapies. Advanced treatments such as targeted biologics, gene therapies, and precision oncology drugs often require expensive molecular testing and companion diagnostics. These costs can limit patient access and create reimbursement challenges, slowing adoption across healthcare systems.

Market Opportunities

Rising Investment in Research and Development

Growing investments in precision medicine research are creating substantial growth opportunities. Increased funding for genomic research, biomarker discovery, AI-based healthcare solutions, and clinical trials is expanding the development pipeline. These investments are helping personalized medicine expand beyond oncology into cardiology, neurology, rare diseases, and preventive healthcare applications.

Market Challenges

Data Privacy and Security Concerns

Personalized medicine relies heavily on genomic and clinical data, making privacy and cybersecurity critical concerns. The growing use of AI-driven analytics platforms and data-sharing networks increases the risk of unauthorized access and data breaches. As a result, healthcare organizations and technology providers must invest significantly in secure data management and regulatory compliance.

Segment Analysis

By Offering

The therapeutics segment dominated the market in 2025 due to strong demand for targeted therapies and biomarker-guided treatment options. Meanwhile, the software and data analytics segment is expected to register the fastest growth with a CAGR of 15.82% during the forecast period.

By Technology

The genomics and molecular testing segment led the market in 2025 and is expected to account for 34.8% market share in 2026. Growing use of next-generation sequencing, genomic profiling, and molecular diagnostics continues to drive segment growth. The liquid biopsy segment is projected to grow at a CAGR of 13.76%.

By Application

The oncology segment held the largest market share in 2025 and is expected to represent 60.8% of the market in 2026. Rising cancer prevalence and increasing use of companion diagnostics are major growth factors. The rare and genetic diseases segment is forecast to grow at a CAGR of 15.83%.

By End User

Hospitals dominated the market in 2025 and are projected to account for 38.3% of the market in 2026, owing to their extensive use of genomic testing, biomarker analysis, and targeted therapies.

Regional Analysis

North America remained the leading regional market with a value of USD 83.77 billion in 2025. The U.S. market is expected to reach USD 83.56 billion in 2026. Europe is projected to grow at a CAGR of 10.54%, supported by government-backed genomics programs. Asia Pacific is expected to reach USD 62.05 billion in 2026, driven by healthcare modernization and precision medicine investments in China, Japan, India, South Korea, and Singapore. India's personalized medicine market is projected to reach USD 6.69 billion in 2026.

Competitive Landscape

Leading companies operating in the market include F. Hoffmann-La Roche Ltd, Myriad Genetics, Thermo Fisher Scientific, AstraZeneca, Guardant Health, Agilent Technologies, Pfizer, Novartis, Illumina, and Bristol-Myers Squibb. These companies are focusing on companion diagnostics, liquid biopsy technologies, genomic testing platforms, AI-enabled interpretation software, and precision oncology solutions to strengthen their market positions.

Conclusion

The personalized medicine market is witnessing strong growth due to increasing adoption of genomic technologies, targeted therapies, companion diagnostics, and AI-powered healthcare solutions. The market size is expected to increase from USD 214.44 billion in 2025 to USD 233.87 billion in 2026, eventually reaching USD 587.02 billion by 2034. Rising prevalence of chronic diseases, expanding research investments, and advancements in precision healthcare technologies will continue to support market expansion. Despite challenges related to treatment costs and data privacy, personalized medicine is expected to transform healthcare delivery and become a cornerstone of future medical practice worldwide.

Segmentation By Offering, Technology, Application, End User, and Region

By Offering * Diagnostics & Testing

• Therapeutics
• Software & Data Analytics
• Others

By Technology * Genomics & Molecular Testing

• Pharmacogenomics
• Biomarker-Based Profiling
• Liquid Biopsy
• Clinical Decision Support & Interpretation Software
• Others

By Application * Oncology

• Rare & Genetic Diseases
• Neurology
• Cardiology
• Infectious Diseases
• Others

By End User * Hospitals

• Specialty Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region * North America (By Offering, Technology, Application, End User, and Country)

• U.S.
• Canada
• Europe (By Offering, Technology, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Offering, Technology, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Offering, Technology, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Offering, Technology, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Personalized Medicine
• 4.2. Prevalence of Key Diseases, By Key Countries/Regions, 2025
• 4.3. Regulatory & Reimbursement Scenario, By Key Countries/Regions
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• 4.5. New Product Launches, By Key Players

5. Global Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Offering
  • 5.1.1. Diagnostics & Testing
  • 5.1.2. Therapeutics
  • 5.1.3. Software & Data Analytics
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. Genomics & Molecular Testing
  • 5.2.2. Pharmacogenomics
  • 5.2.3. Biomarker-Based Profiling
  • 5.2.4. Liquid Biopsy
  • 5.2.5. Clinical Decision Support & Interpretation Software
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Oncology
  • 5.3.2. Rare & Genetic Diseases
  • 5.3.3. Neurology
  • 5.3.4. Cardiology
  • 5.3.5. Infectious Diseases
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals
  • 5.4.2. Specialty Clinics
  • 5.4.3. Diagnostic Laboratories
  • 5.4.4. Academic & Research Institutes
  • 5.4.5. Pharmaceutical & Biotechnology Companies
  • 5.4.6. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Offering
  • 6.1.1. Diagnostics & Testing
  • 6.1.2. Therapeutics
  • 6.1.3. Software & Data Analytics
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Technology
  • 6.2.1. Genomics & Molecular Testing
  • 6.2.2. Pharmacogenomics
  • 6.2.3. Biomarker-Based Profiling
  • 6.2.4. Liquid Biopsy
  • 6.2.5. Clinical Decision Support & Interpretation Software
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Oncology
  • 6.3.2. Rare & Genetic Diseases
  • 6.3.3. Neurology
  • 6.3.4. Cardiology
  • 6.3.5. Infectious Diseases
  • 6.3.6. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals
  • 6.4.2. Specialty Clinics
  • 6.4.3. Diagnostic Laboratories
  • 6.4.4. Academic & Research Institutes
  • 6.4.5. Pharmaceutical & Biotechnology Companies
  • 6.4.6. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Offering
  • 7.1.1. Diagnostics & Testing
  • 7.1.2. Therapeutics
  • 7.1.3. Software & Data Analytics
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Technology
  • 7.2.1. Genomics & Molecular Testing
  • 7.2.2. Pharmacogenomics
  • 7.2.3. Biomarker-Based Profiling
  • 7.2.4. Liquid Biopsy
  • 7.2.5. Clinical Decision Support & Interpretation Software
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Oncology
  • 7.3.2. Rare & Genetic Diseases
  • 7.3.3. Neurology
  • 7.3.4. Cardiology
  • 7.3.5. Infectious Diseases
  • 7.3.6. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals
  • 7.4.2. Specialty Clinics
  • 7.4.3. Diagnostic Laboratories
  • 7.4.4. Academic & Research Institutes
  • 7.4.5. Pharmaceutical & Biotechnology Companies
  • 7.4.6. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Offering
  • 8.1.1. Diagnostics & Testing
  • 8.1.2. Therapeutics
  • 8.1.3. Software & Data Analytics
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Technology
  • 8.2.1. Genomics & Molecular Testing
  • 8.2.2. Pharmacogenomics
  • 8.2.3. Biomarker-Based Profiling
  • 8.2.4. Liquid Biopsy
  • 8.2.5. Clinical Decision Support & Interpretation Software
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Oncology
  • 8.3.2. Rare & Genetic Diseases
  • 8.3.3. Neurology
  • 8.3.4. Cardiology
  • 8.3.5. Infectious Diseases
  • 8.3.6. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals
  • 8.4.2. Specialty Clinics
  • 8.4.3. Diagnostic Laboratories
  • 8.4.4. Academic & Research Institutes
  • 8.4.5. Pharmaceutical & Biotechnology Companies
  • 8.4.6. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Offering
  • 9.1.1. Diagnostics & Testing
  • 9.1.2. Therapeutics
  • 9.1.3. Software & Data Analytics
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Technology
  • 9.2.1. Genomics & Molecular Testing
  • 9.2.2. Pharmacogenomics
  • 9.2.3. Biomarker-Based Profiling
  • 9.2.4. Liquid Biopsy
  • 9.2.5. Clinical Decision Support & Interpretation Software
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Oncology
  • 9.3.2. Rare & Genetic Diseases
  • 9.3.3. Neurology
  • 9.3.4. Cardiology
  • 9.3.5. Infectious Diseases
  • 9.3.6. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals
  • 9.4.2. Specialty Clinics
  • 9.4.3. Diagnostic Laboratories
  • 9.4.4. Academic & Research Institutes
  • 9.4.5. Pharmaceutical & Biotechnology Companies
  • 9.4.6. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Offering
  • 10.1.1. Diagnostics & Testing
  • 10.1.2. Therapeutics
  • 10.1.3. Software & Data Analytics
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Technology
  • 10.2.1. Genomics & Molecular Testing
  • 10.2.2. Pharmacogenomics
  • 10.2.3. Biomarker-Based Profiling
  • 10.2.4. Liquid Biopsy
  • 10.2.5. Clinical Decision Support & Interpretation Software
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. Oncology
  • 10.3.2. Rare & Genetic Diseases
  • 10.3.3. Neurology
  • 10.3.4. Cardiology
  • 10.3.5. Infectious Diseases
  • 10.3.6. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals
  • 10.4.2. Specialty Clinics
  • 10.4.3. Diagnostic Laboratories
  • 10.4.4. Academic & Research Institutes
  • 10.4.5. Pharmaceutical & Biotechnology Companies
  • 10.4.6. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. F. Hoffmann-La Roche Ltd
  • 11.2.2. Myriad Genetics, Inc.
  • 11.2.3. Thermo Fisher Scientific Inc.
  • 11.2.4. AstraZeneca
  • 11.2.5. Guardant Health, Inc.
  • 11.2.6. Agilent Technologies Inc.
  • 11.2.7. Pfizer Inc.
  • 11.2.8. Novartis AG
  • 11.2.9. Illumina Inc.
  • 11.2.10. Bristol-Myers Squibb Company